MOTS-c Safety for Adults 30 to 49: What the Evidence Actually Shows
HealthRX.com
Human safety of MOTS-c in adults 30 to 49 is unknown
Key numbers
- 5 mgNominated injection strengths (5 mg and 10 mg subcutaneous) for compounding; not an established doseSource: fda.gov, as cited Nov 7, 2026
- 0.5 to 15 mg/kgRodent doses studied; these cannot be converted into human dosesSource: fda.gov, as cited Nov 7, 2026
- 20%Lower body weight in high-fat-diet mice given injected MOTS-c, after 8 weeks; animal data onlySource: fda.gov, as cited Nov 7, 2026
At a glance
- Human safety data / none; FDA found no study giving MOTS-c to a person [1]
- FDA status / not an approved drug; no USP or National Formulary monograph; no EMA-authorized product [1]
- Main stated concern for injection / immunogenicity from aggregation and peptide-related impurities [2]
- Adverse-event reports / none retrieved in FDA's database search through March 9, 2025 [1]
- Animal toxicity studies / none identified by FDA [1]
- Established dose / none; the nominated products were 5 mg and 10 mg subcutaneous injections [1]
- Compounding lists / MOTS-c appears on neither FDA list [3][4][5]
- Sport / prohibited at all times by WADA under S4.4.1 [6]
What is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a 16-amino-acid peptide with a molecular weight of about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 by Lee and colleagues in Cell Metabolism [1][7]. In that report its primary target organ appeared to be skeletal muscle, and its cellular actions inhibited the folate cycle and its tethered purine biosynthesis, leading to AMPK activation [7].
The free base and the acetate salt are treated by FDA as different bulk substances, and MOTS-c is a common name rather than an official drug name [1]. It is not an FDA-approved drug and is not a component of one: FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1].
Is there any human safety data for adults 30 to 49?
No. FDA's July 2026 evaluation searched PubMed, Embase, the Cochrane library and other sources and found no clinical study in which MOTS-c, compounded or not, was given to a human; the 12 papers the nominator cited were not clinical studies [1]. FDA also searched its adverse-event database (FAERS) through March 9, 2025 and retrieved no MOTS-c reports [1].
An empty database is not the same thing as safety. FDA found no human exposure data by any route of administration, so safety in humans is unknown [1][2].
One laboratory observation bears on whether an injection can even produce active levels. In vitro, MOTS-c is quickly broken down in human blood, which FDA said raises the question whether injecting it can produce active levels in people [1]. FDA found no pharmacokinetic data for MOTS-c in humans or in live animals [1].
What safety concerns did FDA name?
MOTS-c sits in the 'nominated but withdrawn' table on FDA's page of bulk substances that may raise significant safety risks when compounded — the table that holds substances previously placed in category 2 whose nominators withdrew them [2]. FDA's stated concerns:
- It has not identified any human exposure data on drug products containing MOTS-c administered by any route, and the substance lacks important safety information [2].
- Injectable peptides may pose an immunogenicity risk because of aggregation and peptide-related impurities [2].
- MOTS-c is not well characterized: naming is inconsistent, and there are no impurity, aggregate or endotoxin data [1].
- There are no human safety or effectiveness data and no animal toxicity studies [1].
- The molecular targets are unknown and no dose-response relationships were assessed [1].
FDA added a specific caution about how to read the record: removal from category 2 was not a finding that MOTS-c is safe [2].
What people on Reddit report
Reddit users describing their own injections of MOTS-c, mostly reporting skin reactions at the injection site, with one person noting an energy benefit.
Mots C is the only peptide that gives me irritation at the injection site. I'll have a lump where I inject for a few days after. Unfortunately this seems to happen to a lot of people with Mots C.Read the source discussion
Motsc makes me super itchy at the injection site due to the histamine response So I just stopped I even tried diluting it with more bac waterRead the source discussion
Mots-C I have a very noticeable increase in energy that lasts through the day. Not like a caffeine buzz, just steady energy. It does give me a histamine reaction though so be prepared.Read the source discussion
Funnily enough MOTS-C also elevated my heart rate by about 10bpm which is a reasonably unreported side effect.Read the source discussion
What did the animal studies show?
All of the pharmacology is from cells and rodents.
The 2015 discovery paper reported that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity, with skeletal muscle as the main target [7]. In mice, injected MOTS-c reduced weight gain on a high-fat diet — about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneally — and improved insulin sensitivity and exercise performance [1].
A second line of work looked at aging. In young, middle-aged and old mice, MOTS-c injection improved physical performance, and a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [1][8].
Is there a safe or standard dose?
There is no approved dose and no human dosing study of administered MOTS-c [1]. The nominated products were 5 mg and 10 mg subcutaneous injections, nominated for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity [1]. Those figures describe what was proposed for review, not an established dose.
The rodent doses studied ranged from 0.5 to 15 mg/kg and cannot be converted into human doses [1]. Website protocols are not a recommended dose: FDA noted MOTS-c is marketed on websites alone and in combinations, including an IV cocktail offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging [1].
Where does MOTS-c stand legally?
MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025) [3][4][5]. FDA's category 1 policy of generally not acting against compounders, when conditions are met, therefore does not cover it [3][5]. No outsourcing facility reported compounding it from January 2017 to December 2025 [1].
FDA's staff proposed in a July 2026 briefing document that neither the free base nor the acetate be added to the bulks list, citing the characterization gaps and the existence of FDA-approved treatments for obesity and osteoporosis, two of the nominated uses [1].
FDA's Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it to the bulks list, against the staff recommendation. That vote is advice only and not binding, MOTS-c is not on the list, and adding it requires formal rulemaking [9][10].
HHS has filed a draft enforcement-discretion policy for compounding with six peptides, MOTS-c among them, covering the acetate form given by subcutaneous or intramuscular injection. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with it when conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [10][11]. The notice states that it does not establish rights for any person and is not binding on HHS or the public, and that HHS may revisit it; it is not an approval or a listing [10]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [10].
Does WADA prohibit MOTS-c?
Yes. WADA's Prohibited List names MOTS-c in S4.4.1 among activators of AMP-activated protein kinase, prohibited at all times, in and out of competition [6]. It is on the 2026 List and remains on the 2027 List [6][12]. FDA notes it was already on the 2024 List [1].
Does exercise raise your own MOTS-c?
Human studies have measured natural MOTS-c, not injected MOTS-c. In one study, exercise induced endogenous MOTS-c expression in skeletal muscle and in the circulation; participants were not given the peptide [8]. In a randomized trial of 30 healthy adults assigned to endurance exercise (n=10), resistance exercise (n=10) or control (n=10), circulating humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma peptide levels were not related to fitness [13].
The body making its own MOTS-c does not establish that an injected product is safe: the injected product is a synthetic peptide with no toxicity studies [1].
What this means for a 30-to-49-year-old
The advertised uses (metabolism, weight loss, glucose control, performance and anti-aging) are supported by mouse studies and marketing copy rather than human trials [1]. There is no established dose, and the side-effect profile of injected MOTS-c cannot be described. It is also a WADA-prohibited substance and is not on either FDA compounding list [3][5][6].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Questions worth asking
Frequently asked questions
Is MOTS-c safe for adults aged 30 to 49?
What side effects have been reported with MOTS-c?
Is MOTS-c FDA approved?
What dose of MOTS-c is used?
Can MOTS-c be legally compounded?
Do human studies show MOTS-c works like exercise?
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- Reddit participants. Mots-c (r/BodyHackGuide). Accessed 2026-11-10.
- Reddit participants. Opinion on Mots C and SS-31 (r/PeptideDiscussion). Accessed 2026-11-10.